(Q37738536)

22 August 2017

1 reference

title

Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis (English)

1 reference

stem cell transplantation

22 August 2017

main subject

1 reference

Haefaa Alchalby

1

1 reference

22 August 2017

Nicolaus Kröger

series ordinal

2

1 reference

22 August 2017

publication date

1 April 2010

1 reference

Current hematologic malignancy reports

22 August 2017

published in

1 reference

22 August 2017

volume

5

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

53-61

1 reference

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

22 August 2017

cites work

1 reference

12 December 2020

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT

1 reference

12 December 2020

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation

1 reference

12 December 2020

Allogeneic bone marrow transplantation for primary myelofibrosis

1 reference

12 December 2020

Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

1 reference

12 December 2020

Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.

1 reference

12 December 2020

Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Resea

1 reference

12 December 2020

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia

1 reference

12 December 2020

Myelofibrosis: a review of clinical and pathologic features and treatment

1 reference

12 December 2020

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens

1 reference

12 December 2020

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

1 reference

12 December 2020

Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation

1 reference

12 December 2020

Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation

1 reference

12 December 2020

Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation

1 reference

12 December 2020

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.

1 reference

12 December 2020

Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.

1 reference

12 December 2020

Splenectomy and hemopoietic stem cell transplantation for myelofibrosis

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

1 reference

12 December 2020

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

1 reference

12 December 2020

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

1 reference

12 December 2020

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

Allogeneic bone marrow transplantation for primary myelofibrosis

1 reference

12 December 2020

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

1 reference

12 December 2020

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

12 December 2020

Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading

1 reference

12 December 2020

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis

1 reference

12 December 2020

Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect

1 reference

12 December 2020

A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis

1 reference

12 December 2020

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

1 reference

12 December 2020

No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis

1 reference

12 December 2020

Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis

1 reference

12 December 2020

Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment.

1 reference

12 December 2020

Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect

1 reference

12 December 2020

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

12 December 2020

Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation

1 reference

12 December 2020

Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation

1 reference

12 December 2020

The V617F JAK2 mutation and the myeloproliferative disorders

1 reference

12 December 2020

Pathogenesis of myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

1 reference

12 December 2020

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

1 reference

12 December 2020

Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups

1 reference

12 December 2020

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

12 December 2020

10.1007/S11899-010-0044-Z

Identifiers

DOI

1 reference

22 August 2017

1 reference